Skip to content

Trial of indomethacin in pancreatitis

A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2014-004844-37-ES
Enrollment
40
Registered
2015-05-08
Start date
2015-07-16
Completion date
Unknown
Last updated
2015-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis

Interventions

Trade Name: ARTRINOVO DEBIL SUPOSITORIOS Pharmaceutical Form: Rectal capsule INN or Proposed INN: INDOMETHACIN SODIUM TRIHYDRATE Current Sponsor code: 620385 Concentration unit: mg milligram(s) Conce

Sponsors

Enrique de Madaria Pascual
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients ages 18 or above admitted to hospital with a diagnosis of Acute pancreatitis (AP) based on at least 2 of the followin criteria: (i)abdominal pain characteristic of AP; (ii) serum amylase and/or lipase>= 3 times the upper limit of normal; and/or (iii) characteristic findings of AP on abdominal CT scan . Patients with SIRS (38ºC, heart rate >90/min, respiratory rate >20/min or PaCO212,000/mm3 or >10% bands) upon hospital admission or who develop SIRS within 48 hrs of admission. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: More than 48 hrs since the onset of abdominal paien, absence of SIRS within 48 hrs of presentation, presence of OF, presence of renal dysfunction, active peptic ulcer disease, use of daily NSAIDs within 1 week of presentation and or allergy to NSAIDs.

Design outcomes

Primary

MeasureTime frame
Main Objective: Evaluate the efficacy of rectal indomethacin on attenuating systemis inflammation in patients with AP who also have SIRS;Secondary Objective: Not applicable;Primary end point(s): Reduction in systemic inflammation as measured by change in the mean SIRS score prior to and at 48 hrs following initiation of the intervention.;Timepoint(s) of evaluation of this end point: 48 hrs

Secondary

MeasureTime frame
Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable

Countries

Spain, United States

Contacts

Public ContactEnrique de Madaria Pascual

Enrique de Madaria Pascual

madaria@hotmail.com+34965913975

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026